Induction of cell cycle arrest in human MCF-7 breast cancer cells by cis-stilbene derivatives related to VIOXX.
In our present study, 12 new cis-stilbene derivatives (CRI-1-CRI-13) related to VIOXX((R)) were synthesized and studied for their inhibitory effects on cell cycle progression and anti-estrogenicity in human adenoma breast cancer MCF-7 cells. Based on the different substituents in the cis-stilbene molecule, we studied a possible structure activity relationship (SAR) for the inhibition of the cell cycle, cytotoxicity and (anti-) estrogenicity. The results showed that some cis-stilbenes have a pronounced effect on cell cycle distribution. CRI-5, 7, 10 and 12 caused an arrest of G2/M phase and reduction of G1/S phase in all tested doses (1-50 microM). In addition, some of these cis-stilbenes, have a moderate anti-estrogenic effect around 10 microM. Based on these results a preliminary SAR for cis-stilbene derivatives is suggested in which the presence and position of methoxy or thiomethoxy groups play an essential role in this cell cycle arrest. For this substitution on the para position of the left aromatic ring appears to be a prerequisite. However, the SAR for anti-estrogenicity appears to be different, but experimental information was too limited to define a possible SAR. In conclusion, our study shows that some synthetic cis-stilbene related to VIOXX might have chemopreventive properties that can effectively interfere with the cell cycle distribution of breast tumor cells.
Sangjun
Sunisa
S
Asian Institute of Technology, Mahidol University, Bangkok, Thailand. sunisa@cri.or.th
de Jong
Esther
E
Nijmeijer
Sandra
S
Mutarapat
Thumnoon
T
Ruchirawat
Somsak
S
van den Berg
Martin
M
van Duursen
Majorie B M
MB
D016588:Anticarcinogenic Agents / Q000138:chemical synthesis* / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000473:pathology*; D002453:Cell Cycle / Q000187:drug effects*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D052246:Cyclooxygenase 2 Inhibitors / Q000633:toxicity*; D004965:Estrogen Antagonists / Q000138:chemical synthesis* / Q000494:pharmacology*; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007783:Lactones / Q000633:toxicity*; D013267:Stilbenes / Q000138:chemical synthesis / Q000633:toxicity*; D013329:Structure-Activity Relationship; D013450:Sulfones / Q000633:toxicity*
D016588:Anticarcinogenic Agents; D052246:Cyclooxygenase 2 Inhibitors; D004965:Estrogen Antagonists; D007783:Lactones; D013267:Stilbenes; D013450:Sulfones; C116926:rofecoxib